NEI Research News

The road from discovering a potential drug to getting the therapy into the hands of patients is a long and uncertain one. An NIH program called Blueprint Neurotherapeutics Network helps basic researchers prep for clinical trials and regulatory approval.

New research by National Eye Institute (NEI) investigators shows that while microsaccades seem to boost or diminish the strength of the brain signals underlying attention, eye movements are not drivers of those brain signals.

The digital summit of global partners in vision research discussed opportunities for collaboration.

Researchers at the National Eye Institute (NEI) have discovered that power-producing organelles in the eye’s photoreceptor cells, called mitochondria, function as microlenses that help channel light to these cells’ outer segments.

Part of the Anterior Segment Initiative, the meeting addressed gaps in knowledge, barriers to new therapies, and promising areas for research.

National Eye Institute researchers developed and validated an artificial-intelligence-based method to evaluate patients with Stargardt, an eye disease that can lead to childhood vision loss.

People with age-related macular degeneration (AMD) can undergo cataract surgery without fear of worsening their disease.

Using a stem-cell-derived model, researchers have identified two drug candidates that may slow dry age-related macular degeneration (AMD), a leading cause of blindness for which no treatment exists.

Scientists have discovered that gene therapy and the diabetes drug metformin may be potential treatments for late-onset retinal degeneration (L-ORD), a rare, blinding eye disease.

Findings in mice point to potential therapies for blinding eye disease uveitis and multiple sclerosis